Elliot V. Hersh, DMD, MS, PhD, is currently a Professor of Pharmacology/Oral Surgery at the University of Pennsylvania School of Dental Medicine. He received his DMD degree from UMDNJ-NJDS in 1981 and his MS and PhD degrees from UMDNJ – Graduate School of Biomedical Sciences in 1983 and 1988 respectively. Since arriving at the Penn in 1988, Dr. Hersh has won the Dental School’s Excellence in the Teaching of Basic Science Award 20 different times and was also presented with a University Lindback Award in 1993, the highest teaching honor in the entire University. He has published more than 150 scientific articles, abstracts and book chapters in the areas of dental pharmacology, drug interactions, analgesics and local anesthetics. He is currently collaborating with faculty from the Penn Institute of Translational Medicine and Applied Therapeutics in identifying biomarkers that may predict individual analgesic response to NSAIDs. He remains passionate about providing students and practitioners with evidence-based data to reduce the unnecessary use of, and when needed the prescribing of excessive amounts of immediate-release opioid formulations. His scholarly and research contributions in the areas of local anesthesia and pain control were recognized by the International Association of Dental Research in 2007 when he was presented with the Distinguished Scientist Award in Pharmacology, Therapeutics and Toxicology.

Disclosure: Dr Hersh has received grant funding from Pfizer Consumer Healthcare the maker of Advil® products, NIH/NIDA, and the PENN Medicine Center of Precision Medicine. He has also received consulting moneys from Bayer Pharmaceuticals, the maker of Aleve®. This presentation will contain data showing flurbiprofen use in acute postsurgical dental pain. Currently approved for inflammatory pain of osteoarthritis and rheumatoid arthritis. Has though been used for lots of other pain syndromes off-label.